Age and rising rates of cyclooxygenase-2 inhibitor use: Results from a national survey

Journal of General Internal Medicine

Volumn 21, Issue 3, 2006, Pages 245-250

  Steinman, Michael A ^a,b   McQuaid, Kenneth R ^a   Covinsky, Kenneth E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aged; Anti inflammatory agents; Cyclooxygenase inhibitors; Drug utilization; Nonsteroidal; Physician's practice patterns

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; HISTAMINE H2 RECEPTOR ANTAGONIST; MELOXICAM; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; SALICYLIC ACID DERIVATIVE; VALDECOXIB;

CARDIOVASCULAR DISEASE; HEALTH SURVEY; HUMAN; MEDICAL CARE; MEDICAL PRACTICE; MEDICAL RECORD; OUTPATIENT; PHYSICIAN; PRESCRIPTION; REVIEW; RISK FACTOR;

ADULT; AGE FACTORS; AGED; CONTINENTAL POPULATION GROUPS; CYCLOOXYGENASE 2 INHIBITORS; ETHNIC GROUPS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG;

EID: 33645125741     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2006.00336.x     Document Type: Review

References (41)

1. Wolfe MM Lichtenstein DR Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999 340 1888 99.
2. Sturkenboom MC Burke TA Dieleman JP Tangelder MJ Lee F Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford). 2003 42 suppl 3 iii23 iii31.
3. Dubois RW Melmed GY Henning JM Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004 19 197 208.
4. The management of persistent pain in older persons. J Am Geriatr Soc. 2002 50 S205 S224.
5. Fischer MA Schneeweiss S Avorn J Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004 351 2187 94.
6. Dai C Stafford RS Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med. 2005 165 171 7.
7. Finckh A Aronson MD. Cardiovascular risks of cyclooxygenase-2 inhibitors where we stand now. Ann Intern Med. 2005 142 212 4.
8. Spiegel BM Chiou CF Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum. 2005 53 185 97.
9. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med. 2004 351 1707 9.
10. Mukherjee D Nissen SE Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001 286 954 9.
11. Finucane TE. The AGS' fondness for celecoxib. J Am Geriatr Soc. 2002 50 1602.
12. National Center for Health Statistics. 2002. NAMCS Micro-Data File Documentation [On-line]. Available at. Accessed November 15, 2004.
13. Food and Drug Administration. Electronic Orange Book [On-line]. Available at. Accessed May 19, 2005.
14. National Center for Health Statistics. 1998. NAMCS Data File Documentation (ICPSR version) [On-line]. Available at. Accessed May 19, 2005.
15. National Center for Health Statistics. 1999. NAMCS Micro-Data File Documentation (ICPSR version) [On-line]. Available at. Accessed May 19, 2005.
16. National Center for Health Statistics. 2000. NAMCS Micro-Data File Documentation [On-line]. Available at. Accessed November 20, 2004.
17. National Center for Health Statistics. 2001. NAMCS Micro-Data File Documentation (ICPSR version) [On-line]. Available at. Accessed May 19, 2005.
18. Hooper L Brown TJ Elliott R Payne K Roberts C Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs systematic review. BMJ. 2004 329 948.
19. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002 167 1131 7.
20. Hedner T Samulesson O Wahrborg P Wadenvik H Ung KA Ekbom A. Nabumetone therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs. 2004 64 2315 43.
21. National Center for Health Statistics. Using ultimate cluster models with NAMCS and NHAMCS public use files [On-line]. Available at. Accessed May 19, 2005.
22. McDowell A. (StataCorp). Stratum with only one PSU detected [On-line]. Available at. Accessed May 19, 2005.
23. Mamdani M Rochon PA Juurlink DN et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002 325 624.
24. Steinman MA Sands LP Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med. 2001 16 793 9.
25. Piette JD Heisler M Wagner TH. Cost-related medication underuse among chronically ill adults the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004 94 1782 7.
26. Deeks JJ Smith LA Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis systematic review of randomised controlled trials. BMJ. 2002 325 619 26.
27. Silverstein FE Faich G Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 284 1247 55.
28. Bombardier C Laine L Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000 343 1520 8.
29. Watson DJ Harper SE Zhao PL Quan H Bolognese JA Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000 160 2998 3003.
30. Moore RA Derry S Makinson GT McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005 7 R644 R665.
31. Ofman JJ Badamgarav E Henning JM Knight K Laine L. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents a managed care claims analysis. Am J Med. 2004 116 835 42.
32. Joshua FF Oakley SP Major GA. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. Intern Med J. 2004 34 153 61.
33. Bouee S Charlemagne A Fagnani F et al. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine. 2004 71 214 20.
34. Greenberg JD Bingham CO III. Abramson SB Reed G Sebaldt RJ Kremer J. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis Rheum. 2005 53 12 17.
35. Solomon DH Schneeweiss S Glynn RJ Levin R Avorn J. Determinants of selective cyclooxygenase-2 inhibitor prescribing are patient or physician characteristics more important? Am J Med. 2003 115 715 20.
36. Rahme E Marentette MA Kong SX Lelorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum. 2002 47 595 602.
37. Topol EJ. Arthritis medicines and cardiovascular events - "house of coxibs." JAMA. 2005 293 366 8.
38. Consumers Union and Consumer Reports Best Buy Drugs. The NSAID drugs: prescriptions and prices, 2004 through 1st quarter 2005 [On-line]. Available at. Accessed June 14, 2005.
39. Waxman HA. Memorandum to Democratic Members of House Government Reform Committee: The Marketing of Vioxx to Physicians. [On-line]. Available at. Accessed May 5, 2005.
40. Rosenthal MB Berndt ER Donohue JM Frank RG Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med. 2002 346 498 505.
41. Wright JM Perry TL Bassett KL Chambers GK. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001 286 2398 400.